logo-loader
viewImugene Ltd

Imugene appoints distinguished physician and scientist to the Scientific Advisory Board

The company’s vision is to help transform and improve the treatment of cancer and the lives of the millions of patients who need effective treatments – this vision is backed by a growing body of clinical evidence and peer-reviewed research.

Imugene Ltd - Imugene appoints distinguished physician and scientist to the Scientific Advisory Board
Imugene is a clinical stage immuno-oncology company

Imugene Ltd (ASX:IMU) has appointed professor Prasad S Adusumilli to its newly formed oncolytic virotherapy (OV) Scientific Advisory Board (SAB).

Adusimilli is a world-renowned thoracic surgeon with expertise in the diagnosis and treatment of cancers such as chest, lung, esophageal cancer, mesothelioma, thymoma, mediastinal and chest wall tumours. 

“Distinguished physician and scientist”

Imugene’s managing director and CEO Leslie Chong said: “It is a great honour for Imugene to have such a distinguished physician and scientist join our team.

“Adusumilli has devoted his career and his scientific discoveries for the benefit of cancer sufferers.”

His research focuses on tumour immunology, chimeric antigen receptor (CAR) T-cell therapy, oncolytic viral therapy and combination immunotherapy for cancers.

Over the years, Adusumilli’s team has developed clinically relevant mouse models and modelled biological therapies in these models.

This research has yielded mechanistic data that has been translated and is now in CAR T-cell and combination immunotherapy clinical trials for patients with lung cancer, pleural mesothelioma and breast cancer.

His ongoing research focuses on investigating immuno oncology agent’s efficacy in human ex vivo translational culture systems.

Oncolytic virotherapy

OVs are designed to both selectively kill tumour cells and activate the immune system against cancer cells, with the potential to improve clinical response and survival.

They also have the potential to transform oncology by directly causing tumour cell death and by delivering a potent payload in a targeted fashion that activates the immune system.

Quick facts: Imugene Ltd

Price: 0.0305 AUD

ASX:IMU
Market: ASX
Market Cap: $110.93 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Imugene Ltd named herein, including the promotion by the Company of Imugene Ltd in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Imugene receives $4.13 million R&D tax incentive boost for commercial and...

Imugene Ltd (ASX:IMU) chief executive officer Leslie Chong and visiting US Professor Yuman Fong update Proactive on the progress of the company’s remarkable CF33 oncolytic virotherapy technology, which was acquired in July 2019. Professor Fong is the inventor of the technology and spoke about...

on 12/11/19

2 min read